Regeneron Reports Third Quarter 2018 Financial and Operating Results

TARRYTOWN, N.Y., Nov. 6, 2018 /PRNewswire/ --

• Third quarter 2018 EYLEA®(aflibercept) Injection U.S. net sales increased 7% to$1.02 billionversus third quarter 2017, and third quarter 2018 EYLEA global net sales(1)increased 11% to$1.68 billionversus third quarter 2017

• U.S. launch of Libtayo®(cemiplimab-rwlc) Injection for the treatment of patients with cutaneous squamous cell carcinoma (CSCC) underway

• U.S. launch of Dupixent®(dupilumab) Injection in patients with moderate-to-severe asthma underway

• FDA approval of EYLEA for an every 12-week dosing regimen in patients with wet age-related macular degeneration (wet AMD)

• Positive Phase 3 trial results showed that EYLEA improved diabetic retinopathy and reduced vision-threatening complications

• Positive results reported from Phase 3 Dupixent trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and Phase 3 fasinumab trial in patients with chronic pain from osteoarthritis of the knee or hip

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced financial results for the third quarter of 2018 and provided a business update.

"Regeneron continues to grow and diversify our business, while continuing to deliver very strong financial results.  In addition to EYLEA reaching over$1 billionin quarterly U.S. net sales, we also made significant progress with Dupixent, a key driver of future growth, and launched Libtayo, our first immuno-oncology therapy," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  "Dupixent is now approved in the U.S. for both atopic dermatitis and asthma and under regulatory review for the treatment of adolescents with atopic dermatitis - with another submission planned in chronic rhinosinusitis with nasal polyps.  We also recently reported positive Phase 3 results for EYLEA in diabetic retinopathy, and expect an FDA action on our supplemental application for this indication in the first half of 2019."

($ in millions, except per share data)

Total revenues

$

1,663

$

1,501

11

%

GAAP net income

$

595

$

388

53

%

GAAP net income per share - diluted

$

5.17

$

3.32

56

%

Non-GAAP net income(2)

$

675

$

470

44

%

Non-GAAP net income per share - diluted(2)

$

5.87

$

3.99

47

%

Key Pipeline ProgressRegeneron has twenty product candidates in clinical development, which consist of EYLEA and fully human antibodies generated using the Company'sVelocImmune®technology, including eight in collaboration with Sanofi.  Updates from the clinical pipeline include:

EYLEA®(aflibercept) Injection

• The FDA approved EYLEA for an every 12-week dosing regimen option after one year of effective therapy in patients with wet AMD.

• The FDA accepted for review the supplemental Biologics License Application (sBLA) of EYLEA for the treatment of diabetic retinopathy, with a target action date ofMay 13, 2019.

• The Company announced that the Phase 3 PANORAMA trial evaluating EYLEA in patients with moderately severe and severe non-proliferative diabetic retinopathy met its one-year primary endpoint and key secondary endpoints, including both the improvement of diabetic retinopathy and a reduction in the rate of vision-threatening complications.

• The FDA issued a Complete Response Letter regarding the Chemistry, Manufacturing, and Controls Prior-Approval Supplement (PAS) for the EYLEA pre-filled syringe. The Company expects to compile all the requested information and resubmit the PAS in the first half of 2019.

Dupixent®(dupilumab) Injection

• InOctober 2018, the FDA approved Dupixent as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.

• The Company and Sanofi submitted an sBLA and a Marketing Authorization Application (MAA) for an expanded atopic dermatitis indication in adolescent patients (12–17 years of age). InNovember 2018, the FDA accepted for priority review the sBLA for atopic dermatitis in adolescent patients, with a target action date ofMarch 11, 2019.

• The Company and Sanofi announced positive top-line results from both pivotal Phase 3 placebo-controlled trials evaluating Dupixent in adults with inadequately-controlled CRSwNP.

• A Phase 2/3 study in eosinophilic esophagitis and a Phase 2 study in peanut allergy were initiated.

Praluent®(alirocumab) Injection

• The FDA approved Praluent for the treatment of patients with heterozygous familial hypercholesterolemia (HeFH) undergoing apheresis.

• An sBLA for Praluent as a potential treatment to reduce major adverse cardiovascular events was accepted for review by the FDA, with a target action date ofApril 28, 2019.

• The FDA also accepted for review an sBLA for Praluent for first-line treatment of hyperlipidemia, with a target action date ofApril 29, 2019.

• A Phase 3 study in pediatric patients with homozygous familial hypercholesterolemia (HoFH) was initiated.

Kevzara®(sarilumab) Injection

• A Phase 3 study in polymyalgia rheumatica was initiated.

Libtayo®(cemiplimab-rwlc) Injection

• OnSeptember 28, 2018, the FDA approved Libtayo (cemiplimab-rwlc) for the treatment of patients with metastatic or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

Fasinumabis an antibody targeting Nerve Growth Factor (NGF).

• The Company and Teva announced positive top-line results from a Phase 3 study of fasinumab in patients with chronic pain from osteoarthritis of the knee or hip.

REGN3500is an antibody to IL-33.

• A Phase 2 study in chronic obstructive pulmonary disease (COPD) was initiated.

• In the third quarter of 2018, the Company entered into a collaboration agreement with bluebird bio, Inc. to research, develop, and commercialize novel immune cell therapies for cancer.

Product Revenues:Net product sales were$1.025 billionin the third quarter of 2018, compared to$957 millionin the third quarter of 2017.  EYLEA net product sales inthe United Stateswere$1.022 billionin the third quarter of 2018, compared to$953 millionin the third quarter of 2017.  Overall distributor inventory levels for EYLEA inthe United Statesremained within the Company's one-to-two-week targeted range.

Total Revenues:Total revenues, which include product revenues described above, increased by 11% to$1.663 billionin the third quarter of 2018, compared to$1.501 billionin the third quarter of 2017.  Total revenues include Sanofi and Bayer collaboration revenues of$521 millionin the third quarter of 2018, compared to$482 millionin the third quarter of 2017.  The increase in Sanofi collaboration revenue in the third quarter of 2018 was primarily due to the Company's share of higher net sales of Dupixent and Praluent, partly offset by the ceasing of funding by Sanofi in connection with the Company's Discovery and Preclinical Development Agreement, which ended onDecember 31, 2017, and an increase in the collaboration's Dupixent commercialization expenses.  Bayer collaboration revenue increased in the third quarter of 2018 primarily due to an increase in net profits in connection with higher sales of EYLEA outside the United States.  The increase in other revenue in the third quarter of 2018 was partially due to the recognition of a portion of$80 millionin development milestones achieved in the third quarter of 2018 in connection with the Company's fasinumab collaboration with Teva and Mitsubishi Tanabe Pharma.

The Company adopted Accounting Standard Codification (ASC) 606,Revenue from Contracts with Customers, as ofJanuary 1, 2018.  The Company adopted the standard using the modified retrospective method, and therefore prior period amounts have not been adjusted.  A more complete description of the impact of adopting ASC 606 can be found in the Company's Form 10-Q for the quarterly period endedSeptember 30, 2018.

Refer to Table 4 for a summary of collaboration and other revenue.

Research and Development (R&D) Expenses:GAAP R&D expenses were$557 millionin the third quarter of 2018, compared to$530 millionin the third quarter of 2017.  The higher R&D expenses in the third quarter of 2018 were principally due to an increase in Libtayo development expenses and higher R&D headcount and facilities-related costs, partly offset by a decrease in Dupixent development expenses.  In the third quarter of 2018, R&D-related non-cash share-based compensation expense was$60 million, compared to$70 millionin the third quarter of 2017.

Selling, General, and Administrative (SG&A) Expenses:GAAP SG&A expenses were$369 millionin the third quarter of 2018, compared to$307 millionin the third quarter of 2017.  The higher SG&A expenses in the third quarter of 2018 were primarily due to higher headcount and headcount-related costs and higher contributions to independent not-for-profit patient assistance organizations.  In the third quarter of 2018, SG&A-related non-cash share-based compensation expense decreased to$43 million, compared to$48 millionin the third quarter of 2017.

Income Tax Expense:In the third quarter of 2018, GAAP income tax expense was$41 millionand the effective tax rate was 6.5%, compared to$177 millionand 31.3% in the third quarter of 2017.  The Company's effective tax rate for the third quarter of 2018 was significantly impacted by the law known as the Tax Cuts and Jobs Act (the "U.S. Tax Reform Act"), which reduced the U.S. federal corporate income tax rate from 35% to 21% effectiveJanuary 1, 2018.  The effective tax rate for the third quarter of 2018 was positively impacted, compared to the U.S. federal statutory rate, primarily by the tax benefit associated with tax planning in connection with the U.S. Tax Reform Act, the federal tax credit for research activities, and, to a lesser extent, stock-based compensation and income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate.  During the third quarter of 2018, the Company recorded an income tax benefit of$11.9 millionas an adjustment to the provisional amount recorded as ofDecember 31, 2017for the U.S. Tax Reform Act, which was related to the re-measurement of the Company's U.S. net deferred tax assets.

GAAP and Non-GAAP Net Income(2):GAAP net income was$595 million, or$5.50per basic share and$5.17per diluted share, in the third quarter of 2018, compared to GAAP net income of$388 million, or$3.64per basic share and$3.32per diluted share, in the third quarter of 2017.

Non-GAAP net income was$675 million, or$6.25per basic share and$5.87per diluted share, in the third quarter of 2018, compared to non-GAAP net income of$470 million, or$4.41per basic share and$3.99per diluted share, in the third quarter of 2017.

A reconciliation of the Company's GAAP to non-GAAP results is included in Table 3 of this press release.

The Company's updated full year 2018 financial guidance consists of the following components:

Sanofi collaboration revenue: Sanofireimbursement of Regeneroncommercialization-related expenses

$430 million–$455 million

(previously $455 million–$485 million)

Non-GAAP unreimbursed R&D(2)(4)

$1.190 billion–$1.225 billion

(previously $1.210 billion–$1.260 billion)

Non-GAAP SG&A(2)(4)

$1.330 billion–$1.370 billion

(previously $1.340 billion–$1.390 billion)

Effective tax rate

11%–13%

(previously 13%–16%)

Capital expenditures

$360 million–$390 million

(previously $410 million–$450 million)

(1)

Regeneron records net product sales of EYLEA in the United States.  Outside the United States, EYLEA net product sales comprise sales by Bayer in countries other than Japan and sales by Santen Pharmaceutical Co., Ltd. in Japan under a co-promotion agreement with an affiliate of Bayer.  The Company recognizes its share of the profits (including a percentage on sales in Japan) from EYLEA sales outside the United States within "Bayer collaboration revenue" in its Statements of Operations.

(2)

This press release uses non-GAAP net income, non-GAAP net income per share, non-GAAP unreimbursed R&D, and non-GAAP SG&A, which are financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles ("GAAP").  These non-GAAP financial measures are computed by excluding certain non-cash and other items from the related GAAP financial measure.  Non-GAAP adjustments also include the estimated income tax effect of reconciling items.

The Company makes such adjustments for items the Company does not view as useful in evaluating its operating performance.  For example, adjustments may be made for items that fluctuate from period to period based on factors that are not within the Company's control (such as the Company's stock price on the dates share-based grants are issued or changes in the fair value of the Company's equity investments) or items that are not associated with normal, recurring operations (such as changes in applicable laws and regulations).  Management uses these non-GAAP measures for planning, budgeting, forecasting, assessing historical performance, and making financial and operational decisions, and also provides forecasts to investors on this basis.  Additionally, such non-GAAP measures provide investors with an enhanced understanding of the financial performance of the Company's core business operations.  However, there are limitations in the use of these and other non-GAAP financial measures as they exclude certain expenses that are recurring in nature.  Furthermore, the Company's non-GAAP financial measures may not be comparable with non-GAAP information provided by other companies.  Any non-GAAP financial measure presented by Regeneron should be considered supplemental to, and not a substitute for, measures of financial performance prepared in accordance with GAAP.  A reconciliation of the Company's historical GAAP to non-GAAP results is included in Table 3 of this press release.

(3)

The Company's 2018 financial guidance does not assume the completion of any significant business development transactions not completed as of the date of this press release.

(4)

A reconciliation of full year 2018 non-GAAP to GAAP financial guidance is included below:

GAAP unreimbursed R&D(5)

$

1,400

$

1,450

R&D: Non-cash share-based compensation expense

(210)

(225)

Non-GAAP unreimbursed R&D

$

1,190

$

1,225

GAAP SG&A

$

1,490

$

1,550

SG&A: Non-cash share-based compensation expense

(160)

(180)

Non-GAAP SG&A

$

1,330

$

1,370

(5)

Unreimbursed R&D represents R&D expenses reduced by R&D expense reimbursements from the Company's collaborators and/or customers.

Regeneron will host a conference call and simultaneous webcast to discuss its third quarter 2018 financial and operating results on Tuesday, November 6, 2018, at8:30 AM.  To access this call, dial (800) 708-4539 (U.S.) or (847) 619-6396 (International).  A link to the webcast may be accessed from the "Investors and Media" page of Regeneron's website atwww.regeneron.com.  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.  Founded and led for 30 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in Regeneron's laboratories.  Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through its proprietaryVelociSuite®technologies, such asVelocImmune®which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the Company, please visitwww.regeneron.comor follow @Regeneron on Twitter.

This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements.  Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned; the likelihood and timing of achieving any of the anticipated milestones described in this news release; unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates and new indications for marketed products, including without limitation EYLEA®(aflibercept) Injection, Dupixent®(dupilumab) Injection, Praluent®(alirocumab) Injection, Kevzara®(sarilumab) Injection, Libtayo®(cemiplimab) Injection, fasinumab, and evinacumab; the extent to which the results from the research and development programs conducted by Regeneron or its collaborators may be replicated in other studies and lead to therapeutic applications; ongoing regulatory obligations and oversight impacting Regeneron's marketed products (such as EYLEA, Dupixent, Praluent, Kevzara, and Libtayo), research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), on the commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; the ability of Regeneron's collaborators, suppliers, or other third parties to perform filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance, including without limitation those relating to Sanofi reimbursement of Regeneron commercialization-related expenses, non-GAAP unreimbursed R&D, non-GAAP SG&A, effective tax rate, and capital expenditures; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto, including without limitation the patent litigation proceedings relating to EYLEA, Dupixent, and Praluent, the ultimate outcome of any such litigation proceedings, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition.  A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission.  Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).

This press release and/or the financial results attached to this press release include amounts that are considered "non-GAAP financial measures" under SEC rules.  As required, Regeneron has provided reconciliations of historical non-GAAP financial measures.

TABLE 1

Assets:

Cash and marketable securities

$

4,065,721

$

2,896,074

Accounts receivable - trade, net

1,665,737

1,538,642

Accounts receivable from Sanofi and Bayer

537,208

435,698

Inventories

1,039,679

726,138

Property, plant, and equipment, net

2,524,446

2,358,605

Deferred tax assets

562,818

506,291

Other assets

410,004

302,838

Total assets

$

10,805,613

$

8,764,286

Liabilities and stockholders' equity:

Accounts payable, accrued expenses, and other liabilities

$

1,148,318

$

967,418

Deferred revenue

1,081,792

949,337

Capital and facility lease obligations

707,203

703,453

Stockholders' equity

7,868,300

6,144,078

Total liabilities and stockholders' equity

$

10,805,613

$

8,764,286

TABLE 2

Revenues:

Net product sales

$

1,025,488

$

957,367

$

3,009,779

$

2,739,745

Sanofi collaboration revenue

256,265

245,175

683,508

677,670

Bayer collaboration revenue

264,373

236,625

775,164

640,919

Other revenue

117,370

61,506

314,552

231,446

1,663,496

1,500,673

4,783,003

4,289,780

Expenses:

Research and development

556,972

529,749

1,584,847

1,547,159

Selling, general, and administrative

369,232

306,766

1,064,886

910,520

Cost of goods sold

30,817

46,388

136,010

149,774

Cost of collaboration and contract manufacturing

79,552

57,844

180,918

141,547

1,036,573

940,747

2,966,661

2,749,000

Income from operations

626,923

559,926

1,816,342

1,540,780

Other income (expense), net

8,938

5,679

60,991

(17,036)

Income before income taxes

635,861

565,605

1,877,333

1,523,744

Income tax expense

(41,206)

(177,288)

(253,286)

(498,752)

Net income

$

594,655

$

388,317

$

1,624,047

$

1,024,992

Net income per share - basic

$

5.50

$

3.64

$

15.06

$

9.66

Net income per share - diluted

$

5.17

$

3.32

$

14.14

$

8.84

Weighted average shares outstanding - basic

108,033

106,706

107,828

106,108

Weighted average shares outstanding - diluted

115,088

117,028

114,843

115,994

TABLE 3

GAAP net income

$

594,655

$

388,317

$

1,624,047

$

1,024,992

Adjustments:

R&D: Non-cash share-based compensationexpense

60,404

70,123

160,841

213,174

SG&A: Non-cash share-based compensationexpense

42,898

47,672

118,379

146,192

COGS and COCM: Non-cash share-basedcompensation expense

8,133

7,302

21,432

20,778

Other income/expense: Loss on extinguishmentof debt

—

—

—

30,100

Other income/expense: Gains and losses oninvestments in equity securities(a)

4,852

—

(21,037)

—

Income tax effect of reconciling items above

(23,560)

(42,958)

(55,896)

(141,458)

Income tax expense: Adjustment to previouslyrecorded charge related to enactment of U.S.Tax Reform Act

(11,886)

—

(11,886)

—

Non-GAAP net income

$

675,496

$

470,456

$

1,835,880

$

1,293,778

Non-GAAP net income per share - basic

$

6.25

$

4.41

$

17.03

$

12.19

Non-GAAP net income per share - diluted

$

5.87

$

3.99

$

15.98

$

11.09

Shares used in calculating:

Non-GAAP net income per share - basic

108,033

106,706

107,828

106,108

Non-GAAP net income per share - diluted

115,142

117,819

114,855

116,616

(a)Prior to the quarter ended March 31, 2018, unrealized gains and losses on equity securities were recorded in Other comprehensive income (loss).  In connection with the adoption of Accounting Standards Update 2016-01, unrealized gains and losses on equity securities during the three and nine months ended September 30, 2018 were recorded in Other income (expense), net.

TABLE 4

Sanofi collaboration revenue:

Reimbursement of Regeneron research anddevelopment expenses

$

150,947

$

190,188

$

426,701

$

609,464

Reimbursement of Regeneron commercialization-related expenses

106,902

91,454

299,263

252,866

Regeneron's share of losses in connection withcommercialization of antibodies

(38,924)

(98,315)

(182,595)

(328,998)

Other

37,340

61,848

140,139

144,338

Total Sanofi collaboration revenue

256,265

245,175

683,508

677,670

Bayer collaboration revenue:

Regeneron's net profit in connection withcommercialization of EYLEA outside theUnited States

243,152

205,367

721,522

571,126

Reimbursement of Regeneron developmentexpenses

457

13,378

8,321

26,447

Other

20,764

17,880

45,321

43,346

Total Bayer collaboration revenue

264,373

236,625

775,164

640,919

Total Sanofi and Bayer collaboration revenue

$

520,638

$

481,800

$

1,458,672

$

1,318,589

Other revenue:

Reimbursement of Regeneron research anddevelopment expenses - Teva

$

27,648

$

28,537

$

101,087

$

82,068

Reimbursement of Regeneron research anddevelopment expenses - other

6,291

150

12,875

3,562

Other

83,431

32,819

200,590

145,816

Total other revenue

$

117,370

$

61,506

$

314,552

$

231,446

TABLE 5

EYLEA*

$

1,021,782

$

654,563

$

1,676,345

$

953,279

$

563,705

$

1,516,984

ARCALYST

3,706

—

3,706

4,088

—

4,088

Net product sales recorded byRegeneron

$

1,025,488

$

957,367

Net product sales recorded by Sanofi*:

Dupixent

$

219,605

$

42,957

$

262,562

$

88,509

$

470

$

88,979

Praluent

$

48,386

$

31,778

$

80,164

$

31,789

$

17,613

$

49,402

Kevzara

$

19,894

$

4,950

$

24,844

$

2,666

$

319

$

2,985

ZALTRAP

$

1,512

$

23,863

$

25,375

$

2,982

$

18,710

$

21,692

EYLEA*

$

2,997,829

$

1,944,482

$

4,942,311

$

2,727,132

$

1,590,043

$

4,317,175

ARCALYST

11,950

—

11,950

12,613

—

12,613

Net product sales recorded byRegeneron

$

3,009,779

$

2,739,745

Net product sales recorded by Sanofi*:

Dupixent

$

517,672

$

85,470

$

603,142

$

116,887

$

743

$

117,630

Praluent

$

121,561

$

91,964

$

213,525

$

89,782

$

41,661

$

131,443

Kevzara

$

48,118

$

13,249

$

61,367

$

3,429

$

399

$

3,828

ZALTRAP

$

6,637

$

73,431

$

80,068

$

7,575

$

50,991

$

58,566

* Bayer records net product sales of EYLEA outside the United States and Sanofi records global net product sales of Dupixent, Praluent, Kevzara, and ZALTRAP.  Refer to Table 4 for the Company's share of profits/losses recorded in connection with sales of EYLEA outside the United States and global sales of Dupixent, Praluent, and Kevzara.  Sanofi pays the Company a percentage of aggregate net sales of ZALTRAP.